Kirsty Duncan PhD MP. WILLFUL BLINDNESS There are things we could know, should know, but somehow manage not to know -Alice Stewart -Barry Marshall and.

Slides:



Advertisements
Similar presentations
Chiari Surgical Outcomes Trial PI: Bermans J. Iskandar and Timothy George with collaboration from John Kestle ASAP-funded pilot study ASAP-funded pilot.
Advertisements

How To Guide Action Item 10 seconds Your Link to AHA/ASA 25 seconds Personal Story 25 seconds.
Alzheimer Bulgaria Association May 2012 Brussels 1Brussels, May 2012Association Alzheimer Bulgaria.
Medical Education Outcomes Research Frederick Chen, MD, MPH Center for Primary Care Research Agency for Healthcare Research and Quality June 26, 2003.
Eduardo Cazap, President Global projects under the auspices of UICC.
Year 6 SATS Meeting Wednesday 30th January 2013
Congress How a Bill Really Becomes Law Artemus Ward Department of Political Science Northern Illinois University
Making a Bill Into a Law By Amanda Booth Period 1 Friday November 7, 2003 How a Bill Becomes Law.
Breast Cancer Research Program
Insert hospital logo here Communicating to Improve Quality Training
HORIZON 2020 STEPHEN FOX FOR KEELE UNIVERSITY 26 TH FEBRUARY 2014.
The Role of the MP Aim: To identify how MPs represent their
1 Environment Canada Environnement Canada Bill C-5, Species at Risk Act November 2002.
Physician Assistants Optimizing Patient Care. Presentation Objectives What is a PA? Scope of Practice PAs in Canada PAs benefiting the Health Care System.
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
1.The VLRC came into operation on the 6 th April The Victorian Law Reform Commission Act 2000 gives this body its powers. 3. The VLRC is an independent.
1 THE NEW TPA/g CERTIFICATION PROCESS Mark W. Harris, O.D. Dorothy L. Hitchmoth, O.D. David J. Caban, O.D. PowerPoint adapted by BSK.
It’s still all about the Patient. Narratives Today I’m going to tell you some stories about how I think we can influence GP commissioners. I hope you.
Matt Smith September What are the odds? The February to March 2013 CSA Pass rate for first time applicants was 78%
Handling (and Preventing) Missing Data in RCTs ASENT March 7, 2009 Janet Wittes Statistics Collaborative.
INDIVIDUAL VERSUS TECHNOLOGY Research, treatment and policy - ethical dilemmas Gabrielle Welle-Strand - Researcher, MD, Senior Adviser Pompidou Group –
We need user-led research more now than ever before…
Kirsty Duncan CANADA NEEDS A PAN-CANADIAN STUDENT NUTRITION PROGRAM.
Kirsty Duncan MP. YOUR ACCOMPLISHMENTS -from just two of us fighting for CCSVI on Parliament Hill -CCSVI debated at the Sub-Committee on Neurological.
Kirsty Duncan PhD MP. YOUR SUCCESSES Awareness in 2010 Support for families Mobilization and formation of CCSVI groups across the country Research and.
Exercise your brain ! Enjoy learning!. Abstract Our research is talking about how exercise effect students’ activeness in the class. Some tests were applied.
Blandford Medical Centre Presentation to Patient Forum Group “Patient Survey Results” 21 March 2014.
a story of learning to trust Jesus Jim & Kathy Love.
Obtaining Informed Consent: 1. Elements Of Informed Consent 2. Essential Information For Prospective Participants 3. Obligation for investigators.
Participating actively in decision making as a team and as an individual Investigating ways in which rights can compete and conflict, and understanding.
Winterbourne View Never Again! Working Together. Introductions Carrie AnnRichard.
Short-term outcomes after endovascular treatment for chronic cerebrospinal venous insufficiency (CCSVI) in patients with multiple sclerosis Kenneth Mandato,
Taipei Water Park Explosion Service Report June 28 to July 18, 2015.
Update on the California Dairy Future Task Force and moving forward December 5, 2012 CONFIDENTIAL AND PROPRIETARY Any use of this material without specific.
Canada’s Drug Strategy. 2 Purpose Provide an overview of Canada’s renewed National Drug Strategy  Historical context  Impetus for change  Renewed National.
What is Multiple Sclerosis (MS)? an unpredictable disease of the central nervous system, which can range from relatively benign to somewhat disabling.
A Summary Of Key Findings From A National Survey Of Voters. #07160.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
How JDRF and the Social Media Played a Role in the Artificial Pancreas Campaign By: Stacia Kirby.
Welcome!  The joining of our 5 organizations into one voice on this issue gives us POWER.  We each have our own focus – but we are one in our belief.
Kirsty Duncan PhD MP CCSVI IN CANADA: ASKS TO ANNOUNCEMENTS TO ACTION.
What’s in the news right now related to science???? Flesh eating bacteria.
Local Assessment of Code of Conduct Complaints. 2 Background  On 08 May 2008 – the local assessment of Code of Conduct complaints was implemented due.
Patient Testimonials Below are links to the testimonials of just a few of the many, many people we have helped. We hope that you will allow us to help.
Planning appeals Peter Ford Head of Development Management Planning Committee Training – 30 th July 2015.
Process of a Bill Parliamentary Law Making – Legislative Process © The Law Bank Parliamentary Law Making Process of a bill 1.
© Mark E. Damon - All Rights Reserved Another Presentation © All rights Reserved
بسم الله الرحمن الرحيم جامعة أم درمان الإسلامية كلية الطب و العلوم الصحية - قسم طب المجتمع مساق البحث العلمي / الدفعة 21 Basics of Clinical Trials.
Report Patient Questionnaire 2013 Dr S. J. Swinden Darnall Health Centre 2 York Road.
Community Pharmacy Cheshire & Wirral (CPCW) Helen Murphy Chief Executive Officer Community Pharmacy Cheshire and Wirral.
Kirsty Duncan PhD MP CCSVI IN CANADA: A CALL FOR SCIENCE AND CONSENSUS.
A great man by the name of Mark Twain once said “It is curious that physical courage should be so common in the world and moral courage so rare.” Courage.
Sight Words.
Writing to a Political Figure Sorry gang, the Copy Center (Didn’t) Came thru again.
The State of Patient Safety in Minnesota Jennifer P. Lundblad, PhD, MBA for the BHCAG Community Forum November 11, 2010.
Lobbying your MP: When you’d rather meet than tweet! Training Materials on Refugee Rights March 23, 2016.
THE SADC GENDER PROTOCOL SUMMIT 2014 LEADERSHIP (LESOTHO, MASERU SUN, 14-16/04/2014 ) PRESENTER’S NAME: TIEANG SEFALI PLEASE USE PHOTOGRAPHS, QUOTES AND.
Myanna Duncan Doctoral Researcher Work & Health Research Centre Loughborough University.
Biostatistics Support for Medical Student Research (MSR) Projects Allen Kunselman Division of Biostatistics and Bioinformatics Department of Public Health.
The council’s future role in education June 2016 [Final] Standards First.
Comprehensive Science II Mrs. Paola González
IT Solutions – Improving Timely Access to Health Care
Palliative Care Matters Initiative
-Make history using YOUR story- Fund Cancer Research
The Club Health Assessment
All That You need To Know About Treatments For Inhalants
Things You Need To Know Before Hiring A Live-In Caregiver
Optometry Miranda Engels
NHS Leadership Academy All staff cascade
It’s OK to ask questions
Presentation transcript:

Kirsty Duncan PhD MP

WILLFUL BLINDNESS There are things we could know, should know, but somehow manage not to know -Alice Stewart -Barry Marshall and Robin Warren Human capacity to ignore what is in front of us is staggering -invisible gorilla In order to see more clearly, we must challenge our biases, encourage debate, and not back away from complicated problems

CANADA REQUIRES EVIDENCE-BASED MEDICINE In order to undertake diagnosis and treatment of CCSVI in Canada, clinical trials must be undertaken Based on the evidence presented at the first CCSVI conference, I decided to bring the fight for clinical trials to Parliament Unfortunately, a highly polarized debate regarding whether or not CCSVI causes MS, and whether or not liberation was a cure for MS, dominated academia and the media--rather than the fundamental question, regarding whether or not MS patients improve following the procedure On the one side, there were the neurologists "I think there are going to be millions of dollars spent now to follow a hoax.... If I thought for one instant there was substance to this, I'd be all over it (Freedman)” On the other side, there were the people living with MS

FIGHT FOR CLINICAL TRIALS IN PARLIAMENT In May, 2010, my colleague, Dr. Bennett, and I wrote an open letter to the Health Minister asking for clinical trials for CCSVI and a registry in Canada In May, I asked for an emergency debate in Parliament -a four-hour take-note debate on CCSVI was granted in June The neurological subcommittee I founded held four meetings on CCSVI -we heard from Drs. Zamboni, Simka, Haacke, and McDonald -all said clinical trials were needed In the summer, when I questioned a top-ranking health official, why we could not have a registry, he explained because ‘we don’t know what is being done overseas’

POLITICAL PROCESS Eventually, the Government put in place a political process to decide whether or not to go ahead with clinical trials; in August, the Canadian Institutes of Health Research, in collaboration with the Multiple Sclerosis Society of Canada, convened a ‘meeting of top researchers’, ’with a special emphasis on neurovascular issues including the recently proposed condition called CCSVI’ Sadly, it was an expert group with no experts in the imaging/treatment of CCSVI -leaders, such as Dr. Sandy McDonald, were not consulted, and there was no inclusion of international experts in CCSVI treatment No data were presented from international scientific conferences, no site visits were made to labs and operating theatres -just blind acceptance of a handful of studies, including two which had been published in an astounding six weeks This seems a cursory review at best by ‘top researchers’, particularly when: -55,000-75,000 Canadians suffer with MS; two major conferences had taken place by August, 2010; over 1500 procedures had been performed worldwide by the time of the meeting, with encouraging results in patients with relapsing and progressive forms of the disease; and a large body of research examining the role of abnormal venous vasculature in MS was completely ignored

RESEARCH IGNORED The first observations related to abnormal vasculature in MS appeared in Cruveilhier in 1839, followed by researchers including, Rindfleisch, in 1863, and Putnam in 1937 There is extensive literature examining such areas as: -venous stenosis -cerebral hydrodynamics and venous hypertension -hypoxia -inflammation and cerebral plaques -vascular damage to nerves -reduced perfusion -loss of small medullary vein visibility in MS

AFTER THE AUGUST, 2010 MEETING After the meeting, we were told that CCSVI experts were not included for fear of biasing the discussion -yet researchers, who had vehemently spoken out against the procedure, were included in the group On September 13 th -14 th, 2010, the Federal-Provincial-Territorial Ministers of Health met in St. John's, Newfoundland -what was the agenda, who was present, what presentations and arguments were made regarding CCSVI, and were all sides of the issue presented? And most important, why, in some cases, did provinces change their positions?

LISTENING Over the past year, I am personally in touch with over 1,000 MS patients across Canada -of these, over 350 have now been treated; many suffer PPMS and SPMS I receive three and four personal notes each week and innumerable phone calls detailing their progress -their changes: improved circulation; changes in the color and temperature in their face, hands, and feet; reduction in the searing nerve pain and the constrictive pain; reduction in brain fuzziness; and improvements in motor function, vision and hearing ‘I did not wait for Canada and had my procedure done 3 months ago today in Albany, New York. It took me 5 weeks to feel better - new blood supply in an old body - but I am now reaping new rewards on an almost daily basis. Some of my improvements are: better 3D vision, things no longer look flat, less glare from the sun or snow, amazing night vision. My left foot woke up, no longer numb. My balance has improved on my left side. I think however the greatest gift has been sleep. Now I can sleep deeper, wake up and go to work (part time) and I do not need to nap in the day. I am really enjoying these "placebo" effects!!!!’ ‘I'm busting at the seams to let everyone know, I have just returned from where I had the CCSVI procedure (venoplasty)...I spent a lot of time researching this and decided I wanted to go to one of the best out there, it took two hours I had five balloons 2...the benefits are phenomenal, my numbness on left side disappeared immediately, vision has improved tenfold, I will now be able to read books again ( used to be one of my favourite pastimes), drop foot gone, fatigue gone. I walked the furthest I have walked in over two years 2 days after the procedure, balance is greatly improved but will work on this with physio as well as muscle mass repair.... benefits are PRICELESS:-)’

FIGHT FOR CLINICAL TRIALS IN CANADA I have asked hundreds of written questions of the Government, attended six international conferences on CCSVI -no Government official has ever attended one I take every opportunity to speak on CCSVI in Parliament -thankfully, Canada’s extraordinary MS patients send me petition after petition so I can deliver these in the House of Commons I was thrilled that Drs Haccke, Hubbard and McDonald joined me on Parliament Hill in February -they came at their own cost to speak to Members of Parliament and Senators to ask for follow-up care, clinical trials and a registry We asked the Minister of Finance to fund clinical trials and a registry

POLITICAL PROCESS FAILED MS PATIENTS FOR A YEAR New ‘Scientific Expert Working Group’ -sadly, it has the same flaws as the initial group—namely, no experts, no experience, and conflicts of interests that went undeclared The new group is to analyze interim and final results from seven Canadian and US MS Societies- funded studies, for which we already have answers -namely, that Bulgaria, Canada, Italy, Kuwait, Poland, and the United States report that 87 to 90% of MS patients show one or more venous abnormalities (by MRI/ultrasound by a trained operator), and 97% when angiography is done Canadian MS patients deserve science; they deserve evidence-based medical practices -sadly MS patients couldn’t have evidence-based practices if their Government refused to collect any evidence--either through clinical trials or a registry Canadian patients, who have been travelling overseas since January 2010, have not had their results tracked -one Canadian neurologist, who had had the CCSVI procedure, said to me, ‘if we had collected the evidence in a registry for the last many months, would we still be calling these anecdotal stories?’

LAST WEEK OF JUNE, 2011 June 20 th : welcomed Tim Donovan, and the New Hope for MS tour to Parliament Hill -called on the Government for clinical trials, and announced that Senator Cordy and I would enter Bills into both the House of Commons and the Senate calling for clinical trials for CCSVI June 27 th : Senator Cordy tabled CCSVI bill June 28 th : CIHR’s Scientific Expert Working Group met June 29 th : the Health Minister reversed her position, and announced clinical trials

SCIENCE LARGELY IGNORED 12,500 procedures had been undertaken in over 50 countries worldwide (March 2011) Eight international CCSVI conferences -Dr. Petrov reported that 62% of his 461 patients showed a functional improvement -Dr. Mehta studied 150 consecutive MS patients, who showed more than a 25% increase in quality of life scores (one year after angioplasty) as measured by physiatrists unaware that the surgical procedure had taken place -Dr. Gilhooly reported that of his 125 patients, they show the following improvements: fatigue (60%); mobility (48%); vision (20%); sensory (60%); brain fuzziness (almost 60%); and bladder (over 40%) Reports from returning Canadian MS patients, treated outside Canada Recommendations by the Ontario Association of Neurologists, the Canadian Society of Radiologists, the Canadian Society of Vascular Surgery, and the American Society of Interventional Radiology

MARCH 16 th 2011 LETTER Ìt is a theory based on the results of a small, uncontrolled study from a single site in Italy by Dr. Zamboni. To date, several other research groups conducting carefully controlled studies have failed to reproduce the observation that CCSVI is associated with MS.` No mention of studies presented at the Venous Endovascular Forum in Poland or from the International Society of Neurovascular Disease conference in Italy, and its press release dated March 15th

SEVEN CORRELATIONAL STUDIES Why was virtually no information released about these seven studies on June 29 th, 2011? Are there any preliminary findings in terms of the seven studies and the literature review? What is the prevalence of CCSVI in MS patients across the seven studies? How do these results compare with those reported from around the world? And most importantly, are there unannounced preliminary findings which are sufficiently compelling that a failure to conduct clinical trials would now be considered unethical?

CLINICAL TRIALS: UNANSWERED QUESTIONS Will this be a multi-centre clinical trial? Have "power" calculations been conducted to determine an adequate number of patients to be included in a clinical trial to demonstrate clinical efficacy at the 0.05 level of significance? How many patients can reasonably be expected to be included in the trial? What will be the exclusion/inclusion criteria? What funding will be provided for the clinical trial, and when will funding be available? Will the number of patients participating in the clinical trial simply reflect the amount of money being made available by the Government (i.e. a backward calculation) or will it be based on meaningful statistical requirements?

POSSIBLE ACTION PLAN Ensure proper health care is not refused to a patient on the ground that the patient has chosen to seek, or has obtained, the CCSVI procedure outside Canada Establish an Advisory Panel, composed of experts who have been actively engaged in imaging or treating patients with CCSVI, and patient representatives, who have been treated, to advise on the procedure Provide funding for an ‘Adaptive Phase II/III trial’(i.e. clinical trials for the CCSVI procedure in multiple centres across Canada)

NATURE OF SCIENCE ‘Science is like building a building. You can’t just say you want a 50-story building and then start building the 50th floor first. It doesn’t work that way. Your goal is to get to that 50th story, but you have to build brick by brick. Then others can come along and start building on top of that brick. That’s how science works.’ The more and more independent investigators obtain the same results, the evidence becomes stronger, and science progresses, and becomes an organized body of knowledge--including both (1) ideas that have stood the test of time as well as attacks by fellow scientists, and (2) ideas that have failed those tests and ‘fallen by the wayside’

THE KEY QUESTION Do MS patients’ quality of life improve following treatment for CCSVI? -must endure the rigour of the scientific process, just like any other new hypothesis, but it must not be subject to new or modified rules: -namely, opinion over evidence -single studies that ‘disprove’ theory -failure to collect relevant data -wilful ignorance of any qualitative and quantitative data

100 RESEARCH QUESTIONS Venous system Venous system and MS CCSVI and MS CCSVI diagnosis CCSVI treatment Determining the best CCSVI treatment Possible impacts of CCSVI treatment on MS Patients CCSVI re-stenosis and diagnosis Secondary procedures for CCSV Prevention of CCSVI in the next generation

MS PATIENTS WANT AN INVESTIGATION How emerging science and experts were willfully ignored? How special interests co-opted science? How an organization that was supposed to steadfastly advocate for MS patients flip-flopped on its position? How process was used not to do science? How conflicts of interests went undeclared? How a pioneering surgeon had to risk his reputation? How MS patients were forced to fight the system? How the Minister repeatedly failed to advocate on behalf of suffering Canadians, particularly with regard to follow-up care--especially when we began raising the issue in July with officials? Who was responsible for repeatedly failing to take leadership, and who must be held accountable for the abject abdication of responsibility?

THANK YOU Thank you to the doctors for your science, your compassion, and your courage to be pioneers Thank you for standing strong in the face of adversity—for doing science, and hoping that eventually evidence over egos, politics, and the various Government lobbies will prevail Thank you to those living with MS for your courage, your tireless efforts to help bring clinical trials to Canada... you inspire me every day